Sign in
Active, not recruitingNo phase

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Key facts

Who runs it
Fondazione Italiana Linfomi - ETS
Where
Italy23 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
212 people enrolled
Started
13 Dec 2024
Expected to end
Dec 2026
Type of study
Observational, 2 groups
Treatments tested
  • Zanubrutinib
Record updated
24 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Signed and dated informed consent form
  • Waldenström's macroglobulinemia diagnosis in need of treatment according to ESMO (European Society for Medical Oncology) guideline 2018
  • Patients who received Zanubrutinib according to the Italian CUP or in common practice following Zanubrutinib commercial approval
  • Treatment with zanubrutinib according to current SmPC (Summary of Product Characteristics)
  • Treatment decision before inclusion into this non-interventional study
  • Age ≥18 years

Who cannot take part

  • Patients with disease progression during a BTKi treatment (if pre-treated with BTK, only those intolerants are considered eligible)
  • Contraindications according to SmPC for patients with WM
  • Participation in an interventional clinical trial during zanubrutinib treatment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a non-interventional, observational, retrospective and prospective multicenter Italian study, to describe treatment management and outcomes of Waldenström's Macroglobulinemia (WM) patients treated according to the Italian Compassionate Use Program (CUP) and receiving zanubrutinib following its commercial approval.

The 2 groups in the trial

  • Retrospective cohort

    All patients with Waldenström's macroglobulinemia enrolled in Pre-Reimbursement Access Program (PRAP) of Zanubrutinib, as per Compassionate Use Program (CUP) of Zanubrutinib, and patients treated with commercial drug (Brukinsa®) from PRAP closure to the study start.

  • Prospective cohort

    Patients with Waldenström's macroglobulinemia treated with Zanubrutinibin clinical practice enrolled from the study start up to 12 months.

    Treatment: Zanubrutinib

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval
Record updated
24 August 2026